Duvelisib was the 2nd PI3K inhibitor approved through the FDA, also dependant on a phase III randomized trial.130 The efficacy and safety profile from the drug show up equivalent with those of idelalisib, if not marginally beneficial. Regarding option BTK inhibitors, there are numerous merchandise in enhancement, but only acalabrutinib is permitted